| Literature DB >> 12861474 |
Francesco Locatelli1, Marco D'Amico, Giuseppe Pontoriero.
Abstract
Shire Pharmaceuticals Group plc, under exclusive license from AnorMED Inc (a subsidiary of Johnson Matthey), is developing lanthanum carbonate, a phosphate-binding lanthanum salt, for the potential treatment of hyperphosphatemia in dialysis patients. It is currently in pre-registration in the US, Canada and Western Europe, and earlier stage clinical trials are ongoing in Japan.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12861474
Source DB: PubMed Journal: IDrugs ISSN： 1369-7056